The present analysis was done to estimate the 5-year outcomes and late adverse events of locally advanced sinonasal tumours treated with induction chemotherapy followed by local therapy.
Twenty-five patients with locally advanced esthesioneuroblastoma or sinonasal neuroendocrine tumours treated between August 2010 to August 2014 with induction chemotherapy followed by local therapy were selected. The 5-year outcome and late adverse events (CTCAE version 4.02) were noted. Progression-free survival (PFS) and overall survival (OS) were estimated using the Kaplan Meier method. COX regression analysis was used to identify factors impacting PFS and OS.
The median follow-up was 5.15 years. The 5 year PFS in esthesioneuroblastoma cohort and in SNEC cohort was 63.5 %( 95%CI 28.9-84.7) and 34.6 % (95%CI 10.1-61.1) respectively (P=0.1). The only factor impacting PFS on multivariate analysis was a response to neoadjuvant chemotherapy (p=0.033). The 5 year OS in esthesioneuroblastoma cohort and in SNEC cohort were 91.7% (95%CI 53.9-98.9) and 46.2% (95%CI 19.2-69.6) respectively (p=0.024). Any grade late adverse event was seen in 20 patients (80%). Metabolic late adverse events were seen in 19 patients (76%).
Neoadjuvant chemotherapy in advanced sinonasal cancers is associated with improvement in 5-year outcomes. However, late side effects especially metabolic are seen in these patients and should be evaluated during follow up.
Tata Memorial Hospital.
Has not received any funding.
The author has declared no conflicts of interest.